IXENSOR
27.4.2022 08:02:08 CEST | Business Wire | Press release
iXensor Co., Ltd. (6734. TWO)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426005097/en/
iXensor, the pioneer of mobile health, today announced that Rohto Pharmaceutical Co., Ltd, a multinational pharmaceutical corporation headquartered in Japan, has become the new strategic partner and shareholder. iXensor received Rohto Pharmaceutical's strategic investment to expand its mobile health business globally and accelerate its PixoTech® platform licensing business.
Building on this strategic partnership, Rohto Pharmaceutical will deploy iXensor's patented PixoTech® technology to digitize its new products through a separate technology licensing and joint development agreement, thereby providing Rohto Pharmaceutical's consumers with innovative self-testing portfolios including women's health and infectious diseases in Japan market.
iXensor's first product, PixoTest® Glucose Monitoring System, developed based on its PixoTech® platform, is the world's first US FDA-approved smartphone camera-based blood test dated in 2017. The PixoTech® , currently protected by more than 70 international patents, is iXensor's core technology platform that transforms smartphones into in vitro diagnostic instruments for biomedical analysis in point-of-care testing and self-testing. PixoTech® controls smartphones' camera sensing modules and screen lighting emissions with multiple wavelengths to analyze all types of immunoassay and enzymatic tests through the proprietary algorithm.
Mr. Hidetoshi Segi, Chief Strategy Officer of Rohto Pharmaceutical, commented, "By investing in iXensor, we can deepen our joint efforts on a series of new product developments, thus expanding our testing and diagnostic business through a wave of digital transformation. As the first step, we will receive a technical license for smartphone-based diagnostic devices and apps from iXensor to develop and sell innovative self-testing products."
Dr. Carson Chen, CEO of iXensor, expressed, "This partnership represents the unlimited potential and technical advantage of the PixoTech® platform to transform smartphones into precision medical diagnostic devices. The licensing business of PixoTech® technology started shifting in as the new engine to drive iXensor's growth."
In the post-pandemic era, iXensor endeavors to accelerate the growth of the at-home self-testing market and empower the evolution of the digital health ecosystem through licensing the PixoTech® technology. Thanks to that, PixoTech® can be flexibly applied to the digitalization of various lateral flow tests. In addition, it can shorten the lead time for IVD manufacturers venturing into the digital health business. It can also be applied to develop companion diagnostic or remote monitoring tools for pharmaceuticals to prove the efficacy of new classes of medications with actual test results collected from patients' smartphones with comfort at home.
About Rohto Pharmaceutical
Founded in 1899, Rohto Pharmaceutical is a renowned Japanese company that has successfully commercialized its research and development of consumer and pharmaceutical products worldwide. Rohto Pharmaceutical has established a robust product portfolio, including eye care, skincare, gastrointestinal medicines, and functional foods. Within the test drug business, the novel coronavirus antigen rapid test for medical institutions was launched in response to the global epidemic in addition to the existing pregnancy test, ovulation test, and flu rapid test products.
About iXensor
iXensor, the pioneer of mobile health, turns smartphones into lab-grade mobile medical diagnostics. In 2017, iXensor introduced the PixoTest®
Blood Glucose Monitoring System as the world's first US FDA-approved smartphone camera-based blood test. Based on the PixoTech®
platform, iXensor has ventured into at-home self-testing and clinical point-of-care diagnostics across infectious diseases, women's health, diabetes, and cardiovascular diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005097/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agentic AI Consulting: Sia Accelerates Its Development with More Than 400 Agents on Its Agent Store11.2.2026 12:17:00 CET | Press release
Sia, an international consulting group specializing in strategy, management, and AI, has reached a milestone in its Agentic AI journey. Born in the digital era, the firm now leverages the expertise of more than 3,000 consultants in 19 countries to help organizations scale AI-driven transformation. From GenAI to an Agent Store for All Industries and Functions After unveiling its Generative AI platform to clients in June 2023, the firm announced the launch of its Agent Store in September 2025. Built on a learn-by-design approach, Sia’s Agent Store grew from 50 AI agents to over 400 available for direct consultation, with over a dozen Minimum Viable Products ready for demonstration. Originally introduced as SiaGPT, the platform is now accessible via siagents.ai, reflecting the transition from custom GPTs to fully agentic services. Sia’s AI agents cover a wide range of industries such as Finance, Energy, Public Sector, Healthcare, and Retail and Consumer Goods, and address all corporate fu
BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 2611.2.2026 12:00:00 CET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics thro
OpenX Strengthens EMEA Leadership with Appointment of Natalie Fisher-Brown11.2.2026 11:05:00 CET | Press release
As RVP, EMEA Buyer Development, the established adtech leader will lead buy-side sales and account management across the region. OpenX Technologies, Inc., one of the world’s leading omnichannel supply-side platforms, today announced the appointment of Natalie Fisher-Brown as Regional Vice President, EMEA Buyer Development. Fisher-Brown will lead, develop, and manage OpenX’s buy-side sales and account management organisations across EMEA, with a focus on strengthening key strategic markets and driving long-term growth for partners. In this new role, Fisher-Brown will oversee the development of senior-level relationships across agencies and brands. She will work closely with well-established and emerging partners to build strategic collaborations that support responsible innovation and sustainable growth. Fisher-Brown’s appointment follows recent hires in France and Germany, reflecting OpenX’s continued investment in market expansion as it evolves the role of the SSP to meet the needs of
TVS Motor Delivers Two iQubes to the Governorate of Vatican City State11.2.2026 10:46:00 CET | Press release
Synergy between TVS Motor Italia and Exelentia defines the path towards sustainable and responsible mobility. TVS Motor Company, a global leader in two and three-wheeler mobility, and Exelentia are strengthening their commitment to sustainable and responsible mobility by providing the Governorate of Vatican City State with two TVS iQube electric scooters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210048491/en/ TVS iQube delivered to Governorate of Vatican State City The official delivery, which took place on February 5th, is part of a consolidated collaboration between the Vatican and Exelentia – which is already active in projects focused on innovation and sustainability. This initiative by Exelentia in a partnership of TVS Motor Italia marks a further concrete step in the ecological transition process already undertaken by the Governorate of Vatican City State. This process aims for zero-emission mobility solutions
LTIMindtree Introduces New Brand Identity and Positioning: LTM — The Business Creativity Partner11.2.2026 10:37:00 CET | Press release
LTIMindtree today unveiled their new brand identity and positioning, which marks a defining moment for the Company. Its Board of Directors has also approved a proposal to change the Company name as 'LTM Limited', subject to shareholder and regulatory approvals. The new identity and positioning as the Business Creativity partner reflects how LTM’s technology capabilities and deep domain expertise converge to create meaningful stakeholder value. This defines how competitive advantage is built in the Agentic Enterprise era, where access to technology alone is no longer a differentiator. LTM brings the very best of human insights and intelligent systems for its clients — applying technology with creativity, precision, and accountability. With the new name and positioning, the Company is also signaling a clear call to action: "It’s time to Outcreate". For its clients, Outcreate is how LTM thinks disruptively, reframes industries, and owns business outcomes through Business Creativity. Toget
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom